GlaxoSmithKline To Pay $75M To Settle Patent Suit

Law360, New York (May 25, 2004, 12:00 AM EDT) -- GlaxoSmithKline has agreed to pay $75 million dollars to settle a drug patent lawsuit brought by a consumer group that had accused the U.K. drug maker of using illegal tactics to maintain its patent on the anti-inflammatory drug Relafen and keep a cheaper generic version off the market.

The settlement, which must be approved by the U.S. District Court Judge William G. Young in Boston, is over a lawsuit brought last year by the consumer group Prescription Access Litigation.

PAL, a nationwide coalition of 93 consumer...
To view the full article, register now.